Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome - Concepedia

Concepedia

Publication | Open Access

Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome

DOI Full Paper Access

16

Citations

28

References

2022

Year

Flávio Signorelli, Gustavo Guimarães Moreira Balbi, Nádia Emi Aikawa, Clóvis A. Silva, Léonard de Vinci Kanda Kupa, Ana Cristina de Medeiros Ribeiro, Emily Figueiredo Neves Yuki, Sandra Gofinet Pasoto, Carla GS Saad, Eduardo Ferreira Borba,

Abstract

We provided novel evidence that Sinovac-CoronaVac has high immunogenicity and safety profile in PAPS. Furthermore, Sinovac-CoronaVac did not trigger thrombosis nor induced changes in aPL production.

References

	Year	Citations

Page 1